Ebola primary prevention
|
Ebola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Postmortem Care |
|
Case Studies |
|
Ebola primary prevention On the Web |
|
American Roentgen Ray Society Images of Ebola primary prevention |
|
Risk calculators and risk factors for Ebola primary prevention |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Vaccines have been produced for both Ebola [1] and Marburg[2] that were 99% effective in protecting a group of monkeys from the disease. These vaccines are based on either a recombinant Vesicular stomatitis virus or a recombinant Adenovirus[3] carrying the Ebola spikeprotein on its surface. Early human vaccine efforts, like the one at NIAID in 2003, have so far not reported any successes.[4] The biggest problem with the vaccine is that unless the patient is given it near the onset of the virus (1-4 days after the symptoms begin) then there will be too much damage to the human body to repair, ie: ruptured arteries and capillaries, vomiting, and other symptoms which may still cause enough harm to kill or seriously traumatize the patient.
References
- ↑ Jones, Steven (2005). "Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses". Nature Medicine. 11 (7): 786–790. doi:10.1038/nm1258. Unknown parameter
|coauthors=ignored (help) - ↑ Hevey, M (1998). "Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates". Virology. 251 (1): 28–37. doi:10.1006/viro.1998.9367. Unknown parameter
|coauthors=ignored (help) - ↑ Sullivan, Nancy (2003). "Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates". Nature. 424 (6949): 681–684. doi:10.1038/nature01876. Unknown parameter
|coauthors=ignored (help) - ↑ "NIAID Ebola Vaccine Enters Human Trial" (Press release). National Institute of Allergy and Infectious Diseases. 2003-11-18.